Cancers & treatments·Regimen libraryFirst line

Nivolumab + relatlimab

Checked 2026-09-09

Unresectable or metastatic melanoma, first line

One cycle

every 28 days

28-day cycle, until progressionIntravenous

Components

Drug	Dose	Route	Days	Note
Nivolumab + relatlimab (fixed dose) Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)	480 mg nivolumab / 160 mg relatlimab	IV	D1

Cycles

until progression

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Used in

Melanoma

Trials

RELATIVITY-047

Products

Relatlimab + nivolumab

Source

RELATIVITY-047, NEJM 2022

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Nivolumab + ipilimumab (melanoma)

Unresectable or metastatic melanoma, especially with brain metastases or PD-L1-negative disease

every 21 days × 4

Pembrolizumab monotherapy

Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)

every 21 days

Dabrafenib + trametinib

BRAF V600-mutant melanoma (adjuvant 1 year or metastatic), NSCLC, anaplastic thyroid cancer and tumour-agnostic use

every 28 days

All regimens Doxorubicin →